Prospera Insights
Back to queue

ITI Pharma and Healthcare Fund

ITI Mutual Fund · 149268 · Quant Rank #337

Not RecommendableFully Researched (Deep)Prospera Research Confidence: MEDIUM
ANALYST_REVIEWED

Research Confidence reflects source quality and evidence depth — it is independent of the score below. A fund can score highly with low confidence, or moderately with high confidence.

Real Evidence
CategoryPH
AUM₹263 Cr
Benchmark—
RiskometerVery High
TER0.58%
InceptionInsufficient data
Track RecordInsufficient data
Fund ManagerNilay Dalal and Animesh Singh
AUM Floor₹300 Cr
Min Track3 yrs
Max Alloc12%
Returns vs Benchmark
WindowFundBenchmark
Calculated Parameters
FMT4/10
AMQ3/10
AUTInsufficient data — no real 3-months-ago AUM evidence (AMFI's live feed only carries current + ~1-month-ago; needs a genuine dated snapshot from an earlier sync)
ERS7/10
Structural Gates
Gate 1 — EligibilityEXCLUDED

AUM floor: FAIL · Track record: UNKNOWN · SEBI: UNKNOWN

Gate 2 — Quant ScreenFAIL
Gate 3 — Top 10FAIL
Gate 4 — Top 5FAIL
Gate 5 — Top 2 ICFAIL
Candidate's 32.7 would rank #3 among 2 real existing category scores (top 2 = recommendable).
Analyst Name
MOM — Momentum
7% weight
Deep Research

3–6M price+flow vs benchmark · 0 = N/A · 1 = Worst · 5 = Average · 10 = Best

Last scored by Claude (V7 Deep Research Pass — Research Quality Review, 2026-08-27) on 8/27/2026, 8:50:16 AM

CON — Consistency
10% weight
Deep ResearchConfidence: HIGH

3Y/5Y quartile rank stability · 0 = N/A · 1 = Worst · 5 = Average · 10 = Best

Last scored by Claude (V7 Deep Research Pass — Research Quality Review, 2026-08-27) on 8/27/2026, 8:50:16 AM

PQT — Portfolio Quality
11% weight
Deep ResearchConfidence: MEDIUM

PE, concentration, churn · 0 = N/A · 1 = Worst · 5 = Average · 10 = Best

Last scored by Claude (V7 Deep Research Pass — Research Quality Review, 2026-08-27) on 8/27/2026, 8:50:16 AM

FMQ — Fund Mgr Quality
12% weight
Deep ResearchConfidence: MEDIUM

Philosophy, communication, style drift · 0 = N/A · 1 = Worst · 5 = Average · 10 = Best

Last scored by Claude (V7 Deep Research Pass — Research Quality Review, 2026-08-27) on 8/27/2026, 8:50:16 AM

VAL — Valuation Risk
10% weight
Deep Research

Portfolio PE/PB vs category avg · 0 = N/A · 1 = Worst · 5 = Average · 10 = Best

Last scored by Claude (V7 Deep Research Pass — Research Quality Review, 2026-08-27) on 8/27/2026, 8:50:16 AM

STW — Sector Tailwinds
9% weight
Deep ResearchConfidence: MEDIUM

Policy/macro drivers 12-18M · 0 = N/A · 1 = Worst · 5 = Average · 10 = Best

Last scored by Claude (V7 Deep Research Pass — Research Quality Review, 2026-08-27) on 8/27/2026, 8:50:16 AM

DSP — Downside Protection
8% weight
Deep Research

Max DD, Sortino, bear markets · 0 = N/A · 1 = Worst · 5 = Average · 10 = Best

Last scored by Claude (V7 Deep Research Pass — Research Quality Review, 2026-08-27) on 8/27/2026, 8:50:16 AM

OPP — Outperformance Prob.
8% weight
Deep ResearchConfidence: MEDIUM

Analyst 12M alpha probability · 0 = N/A · 1 = Worst · 5 = Average · 10 = Best

Last scored by Claude (V7 Deep Research Pass — Research Quality Review, 2026-08-27) on 8/27/2026, 8:50:16 AM

THS — Thesis Strength
2% weight
Deep ResearchConfidence: MEDIUM

Analyst 12-24M thesis conviction · 0 = N/A · 1 = Worst · 5 = Average · 10 = Best

Last scored by Claude (V7 Deep Research Pass — Research Quality Review, 2026-08-27) on 8/27/2026, 8:50:16 AM

V6 Final Score
32.7
/ 100 — Final Score
AVOID
MOM
0.0
CON
4.0
PQT
5.5
FMQ
6.0
VAL
0.0
STW
5.4
DSP
0.0
OPP
3.2
FMT
3.2
AMQ
1.8
AUT
—
ERS
2.8
THS
0.8
Data-limited: AUT (insufficient data — never defaulted to 0)
Source Evidence (8)
Fund ManagerNilay Dalal and Animesh Singh
Value Research Online — public fund page as of 2026-08-27
Fund Manager - Managing SinceNovember 08, 2021
Value Research Online — public fund page as of 2026-08-27
Value Research Rating2 out of 5 stars
Value Research Online — public fund page as of 2026-08-27
Top 5 HoldingsSun Pharmaceutical 13.26%, Divi's Lab 7.97%, Apollo Hospitals 6.05%, Max Healthcare 5.05%, Torrent Pharma 4.84% (top-5 total 37.17%)
Value Research Online — public fund page as of 2026-08-27
AUM (Cr.)263
Value Research Online — public fund page as of 2026-08-27
Total Expense Ratio - Direct Plan (%)0.58
Value Research Online — public fund page as of 2026-08-27
Riskometer (Scheme)Very High
Value Research Online — public fund page as of 2026-08-27
AMC Total AUM (Lakh Cr.)0.11302
AMFI quarterly AAUM disclosure (Apr–Jun 2026), via RightAdvise aggregation of official AMFI figures as of 2026-06-30
Audit Log
MOM ∅ → 0 by Claude (V7 Deep Research Pass — Research Quality Review, 2026-08-27) · 8/27/2026, 8:50:16 AM
“[DEEP RESEARCH] No real return-vs-benchmark figure collected. Scored 0 (N/A).”
CON ∅ → 4 by Claude (V7 Deep Research Pass — Research Quality Review, 2026-08-27) · 8/27/2026, 8:50:16 AM
“[DEEP RESEARCH] Real Value Research rating is 2 out of 5 stars, confirmed directly on the fund's own VR page. Approved substitution: 2★ = 4.”
PQT ∅ → 5 by Claude (V7 Deep Research Pass — Research Quality Review, 2026-08-27) · 8/27/2026, 8:50:16 AM
“[DEEP RESEARCH] Real top-5 holdings: Sun Pharmaceutical 13.26%, Divi's Lab 7.97%, Apollo Hospitals 6.05%, Max Healthcare 5.05%, Torrent Pharma 4.84% (top-5 total 37.17%) — meaningful concentration in Sun Pharma specifically, reputable names overall.”
FMQ ∅ → 5 by Claude (V7 Deep Research Pass — Research Quality Review, 2026-08-27) · 8/27/2026, 8:50:16 AM
“[DEEP RESEARCH] Real managers: Nilay Dalal and Animesh Singh, managing since November 8, 2021 — a real, moderate tenure (~5 years) on this specific scheme.”
VAL ∅ → 0 by Claude (V7 Deep Research Pass — Research Quality Review, 2026-08-27) · 8/27/2026, 8:50:16 AM
“[DEEP RESEARCH] No PE/PB evidence found. Scored 0 (N/A).”
STW ∅ → 6 by Claude (V7 Deep Research Pass — Research Quality Review, 2026-08-27) · 8/27/2026, 8:50:16 AM
“[DEEP RESEARCH] Real, current sector-level tailwind in Indian pharma/healthcare; portfolio reasonably diversified across manufacturing and hospital names.”
DSP ∅ → 0 by Claude (V7 Deep Research Pass — Research Quality Review, 2026-08-27) · 8/27/2026, 8:50:16 AM
“[DEEP RESEARCH] No real drawdown evidence found. Scored 0 (N/A).”
OPP ∅ → 4 by Claude (V7 Deep Research Pass — Research Quality Review, 2026-08-27) · 8/27/2026, 8:50:16 AM
“[DEEP RESEARCH, analyst judgment] Real, below-average 2-star rating and meaningful single-stock concentration temper conviction despite a moderate real manager tenure.”
THS ∅ → 4 by Claude (V7 Deep Research Pass — Research Quality Review, 2026-08-27) · 8/27/2026, 8:50:16 AM
“[DEEP RESEARCH] Standard pharma-sector mandate; the real below-average VR rating is genuine evidence against strong thesis conviction for this specific fund.”